Segment Data

12 Months Ended

Sep. 30, 2011

Segment Data [Abstract]

Segment Data

Note 6 — Segment Data

The Company’s organizational structure is based upon its three principal business segments: BD Medical (“Medical”), BD Diagnostics (“Diagnostics”) and BD Biosciences (“Biosciences”). These segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services.

The Medical segment produces a broad array of medical devices that are used in a wide range of healthcare settings. The principal product lines in the Medical segment include needles, syringes and intravenous catheters for medication delivery (including safety-engineered and auto-disable devices); prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes; prefillable drug delivery devices provided to pharmaceutical companies and sold to end-users as drug/device combinations; regional anesthesia needles and trays; sharps disposal containers; and closed-system transfer devices.

The Diagnostics segment produces products for the safe collection and transport of diagnostic specimens, as well as instrument systems and reagents to detect a broad range of infectious diseases, healthcare-associated infections (“HAIs”) and cancers. The principal products and services in the Diagnostics segment include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems for infectious diseases and women’s health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; and plated media.

The Biosciences segment produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. The principal product lines in the Biosciences segment include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; cell imaging systems; laboratory products for tissue culture and fluid handling; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing.

The Company evaluates performance of its business segments and allocates resources to them primarily based upon operating income. Segment operating income represents revenues reduced by product costs and operating expenses. From time to time, the Company hedges against certain forecasted sales of U.S.-produced products sold outside the United States. Gains and losses associated with these foreign currency translation hedges are reported in segment revenues based upon their proportionate share of these international sales of U.S.-produced products.

Distribution of products is primarily through independent distribution channels, and directly to end-users by BD and independent sales representatives. No customer accounted for 10% or more of revenues in any of the three years presented.

Revenues(A)	2011			2010			2009
Medical	$	4,007,304		$	3,796,432		$	3,556,694
Diagnostics		2,480,477			2,318,879			2,226,219
Biosciences		1,341,123			1,257,022			1,203,809
	$	7,828,904		$	7,372,333		$	6,986,722
Segment Operating Income
Medical	$	1,181,404		$	1,118,319		$	1,049,236
Diagnostics		636,361			607,411			607,250
Biosciences		376,389			354,229			362,344
Total Segment Operating Income		2,194,154			2,079,959			2,018,830
Unallocated Expenses(B)		(477,891	)		(418,799	)		(440,239	)(C)
Income From Continuing Operations Before Income Taxes	$	1,716,263		$	1,661,160		$	1,578,591
Segment Assets
Medical	$	3,928,241		$	3,527,457		$	3,706,086
Diagnostics		2,269,797			2,301,586			1,998,490
Biosciences		1,332,246			1,059,774			989,299
Total Segment Assets		7,530,284			6,888,817			6,693,875
Corporate and All Other(D)		2,900,144			2,761,877			2,610,749
	$	10,430,428		$	9,650,694		$	9,304,624
Capital Expenditures
Medical	$	366,915		$	368,857		$	407,884
Diagnostics		93,435			108,941			102,432
Biosciences		37,220			49,821			55,646
Corporate and All Other		17,815			9,687			19,234
	$	515,385		$	537,306		$	585,196
Depreciation and Amortization
Medical	$	248,091		$	253,109		$	243,445
Diagnostics		163,313			163,392			136,690
Biosciences		76,861			72,319			73,067
Corporate and All Other		15,824			13,293			11,402
	$	504,089		$	502,113		$	464,604

(A)	Intersegment revenues are not material.
(B)	Includes primarily interest, net; foreign exchange; corporate expenses; and share-based compensation expense.

(C)	Includes charge associated with the settlement with the direct purchaser plaintiffs (which includes BD’s distributors) in certain antitrust class actions.
(D)	Includes cash and investments and corporate assets.

Revenues by Organizational Units	2011		2010		2009
BD Medical
Medical Surgical Systems	$	2,081,733	$	2,010,009	$	1,889,314
Diabetes Care		866,477		785,759		714,937
Pharmaceutical Systems		1,059,094		1,000,664		952,443
	$	4,007,304	$	3,796,432	$	3,556,694
BD Diagnostics
Preanalytical Systems	$	1,277,793	$	1,197,807	$	1,143,431
Diagnostic Systems		1,202,684		1,121,072		1,082,788
	$	2,480,477	$	2,318,879	$	2,226,219
BD Biosciences
Cell Analysis	$	1,024,445	$	951,238	$	904,517
Discovery Labware		316,678		305,784		299,292
	$	1,341,123	$	1,257,022	$	1,203,809
	$	7,828,904	$	7,372,333	$	6,986,722

Geographic Information

The countries in which the Company has local revenue-generating operations have been combined into the following geographic areas: the United States (including Puerto Rico), Europe, Asia Pacific and Other, which is comprised of Latin America, Canada, and Japan.

Revenues to unaffiliated customers are based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location.

	2011		2010		2009
Revenues
United States	$	3,355,769	$	3,286,565	$	3,130,165
Europe		2,497,278		2,386,965		2,408,319
Asia Pacific		817,323		684,319		563,390
Other		1,158,534		1,014,484		884,848
	$	7,828,904	$	7,372,333	$	6,986,722
Long-Lived Assets
United States	$	3,140,395	$	2,841,639	$	2,469,952
Europe		1,461,085		1,145,043		1,150,655
Asia Pacific		300,006		258,879		231,257
Other		590,544		617,323		537,214
Corporate		270,067		282,560		268,592
	$	5,762,097	$	5,145,444	$	4,657,670